Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label multicenter study of TR115 in ARID1A-mutant advanced solid tumors
CTR20263369Phase 2Active
- Sponsor
- Tarapeutics Science Inc
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of TR115 in Nonhematologic neoplasms, clear cell ovarian cancer, endometrial cancer (EC), gastric cancer (GC), transitional cell carcinoma (TCC), sponsored by Tarapeutics Science Inc. Started Sep 2026; status: active.
02
Drugs
TR115
03
Conditions
Nonhematologic neoplasmsclear cell ovarian cancerendometrial cancer (EC)gastric cancer (GC)transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on CTR20263369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263369.